<DOC>
	<DOCNO>NCT02675517</DOCNO>
	<brief_summary>The primary objective study measure change physical function - serve surrogate physical activity exercise capacity - COPD patient treat Spiolto® Respimat® approximately 6 week . A secondary objective evaluate patient¿s general condition ( physician¿s evaluation ) visit 1 ( baseline visit start study ) visit 2 ( final visit end study , approx . 6 week visit 1 ) , well patient satisfaction Spiolto® Respimat® visit 2 .</brief_summary>
	<brief_title>Assessment Physical Functioning Handling Spiolto® Respimat® Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Requiring Long-acting Dual Bronchodilation Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent prior participation 2 . Female male patient = 40 year age 3 . Patients diagnose COPD require longacting dual bronchodilation ( LAMA + LABA ) treatment accord approve Spiolto® Respimat® SmPC COPD GOLD guideline recommendation Exclusion criterion : 1 . Patients contraindication accord Spiolto® Respimat® SmPC 2 . Patients treat LABA/LAMA combination ( free fix dose ) previous 6 month 3 . Patients continue LABAiCS treatment additionally treat Spiolto® Respimat® order avoid double dose longacting betaagonists 4 . Patients followup possible enrol site plan study period approx . 6 week 5 . Pregnancy lactation 6 . Patients currently list lung transplantation 7 . Current participation clinical trial noninterventional study drug device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>